Lucido JJ, Penoncello GP, Laughlin BS, Armstrong MD, Lo SG, Rivera JN, Tang X, Chungbin SJ, Breen WG, Mangold AR, Comfere NI, Lester SC, Rule WG, Deufel CL, and Foster MG
Purpose: Purpose: Subtotal skin electron beam therapy may be an option for patients with cutaneous lymphoma receiving radiation therapy to treat large areas of their skin but may benefit from sparing specific areas that may have had previous radiation therapy, are of specific cosmetic concern, and/or show no evidence of disease. We report here on the design, implementation, and dosimetric characteristics of a reusable and transparent customizable shield for use with the large fields used to deliver total skin electron beam therapy at extended distance with a conventional linear accelerator., Methods and Materials: A shield was designed and manufactured consisting of acrylic blocks that can be mounted on a steel frame to allow patient-specific shielding. The dosimetry of the device was measured using radiochromic film., Results: The shield is easy to use and well-tolerated for patient treatment, providing minimal electron transmission through the shield with a sharp penumbra at the field edge, with no increase in x-ray dose. We report on the dosimetry of a commercial device that has been used to treat more than 30 patients to date., Conclusions: The customizable shield is well suited to providing patient-specific shielding for subtotal skin electron beam therapy., Competing Interests: William Breen reports being on the scientific advisory board for GE Healthcare, with all payments made to his institution. John Lucido reports receiving an honorarium paid to his institution for work as grant referee for Global Bridges Oncology and consulting fees paid to his institution by Varian Medical Systems. Aaron Mangold reports currently receiving research grants paid to his institution by Regeneron, Corbus, Incyte, Pfizer, Eli Lilly, Argenyx, Palvella, Abbview, Priovant, and Merck and previous research grants in the past 36 months for Kyowa Kirin, Miragen, Sun Pharma, Elorac, Janssen, and Novartis. He also is currently receiving consulting fees paid to him from Janssen and Boehringer Ingelheim and paid to his institution from Argenyx, Incyte, Regeneron, Clarivate, and Pfizer, previously received consulting fees paid to him from Kyowa Kirin, Clarivate, Soligenix, Phlecs, Incyte, Eli Lilly, Momenta, UCB, and Bristol Myers Squibb, and is currently receiving payment for manuscript writing (for a separate manuscript) from Janssen. He holds a patent for “Topical Ruxolitinib for Treating Lichen Planus” (PCT/US2021/053149; 63/086,898) and has filed for a patent for “Methods and Materials for Assessing and Treating Cutaneous Squamous Cell Carcinoma” (63/423,254). Aaron Mangold is also currently on the Advisory Board for Bristol Myers Squibb currently the President of Pacific Dermatology Society, the Chair of the Community Outreach Committee for the American Academy of Dermatology, on the Board of Directors for the US Cutaneous Lymphoma Consortium, was previously the President of the Arizona Dermatology and Dermatological Society and a Board Member for the Arizona Medical Association (all unpaid), has personal stock ownership of Intellia Therapeutics and Editas, and is receiving medical writing support from Pfizer and Janssen. Chris Deufel reports being a board member of the American Brachytherapy Society., (© 2023 The Author(s).)